MVP与HVP方案治疗晚期NSCLC前瞻随机研究  

A Prospective Randomized Sdudy Comparing MVP and MVP Regimens in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：高建飞[1] 杜光祖[1] 章必成[1] 张新华[1] 王军[1] 朱宇泽[1] 欧武陵[1] 

机构地区：[1]广州军区武汉总医院肿瘤血液科,430070

出　　处：《肿瘤防治研究》2004年第9期579-580,共2页Cancer Research on Prevention and Treatment

摘　　要：目的　比较MVP(MMC +VDS +DDP)与HVP(HCPT +VDS +DDP)方案治疗晚期非小细胞肺癌 (NSCLC)的近期、远期疗效和不良反应。方法　将 88例NSCLC随机分为MVP组和HVP组 ,分别给予MVP和HVP方案化疗 3～ 5周期 ,按WHO标准评定疗效和不良反应。结果　两组有效率 (CR +PR)分别为 36 %和 2 6 % ,二组间疗效差异无显著性意义 (P >0 .0 5 )。二组中位缓解期、中位生存期、1年生存率和 2年生存率相似。二组主要毒副反应有骨髓抑制和消化道反应 ,二组毒副反应相似。结论　MVP方案疗效稍高于HVP方案 。Objective To evaluate the recent and long response and toxicity of MVP and HVP regimens in the treatment of advanced NSCLC. Methods A total of 88 cases with advanced NSCLC was randomized into two groups: MVP group (MMC+VDS+DDP), HVP group (HCPT+VDS+DDP). All patients received 3～5 cycles of chemotherapy except 4 patients. Results The response rate was 36%(15/42) in the MVP and 26%(11/42) in the HVP, no significant difference was detected between the groups (P>0.05). No significant difference was detected in the grade Ⅲ～Ⅳ leukopenia, grade Ⅲ～Ⅳ thrombocytopenia, grade Ⅲ～Ⅳ nausea and vomiting and grade Ⅲ～Ⅳ constipation between the groups. Conclusion The response rate of MVP regimen is slightly higher than HVP regimen. MVP regimen should be selected firstly between the regimens in the chemotherapy of advanced NSCLC.

关 键 词：非小细胞肺癌 化疗 MVP方案 HVP方案 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]